Preventing evolutionary rescue in cancer
Abstract
AO_SCPLOWBSTRACTC_SCPLOWFirst-line cancer treatment frequently fails due to initially rare therapeutic resistance. An important clinical question is then how to schedule subsequent treatments to maximize the probability of tumour eradication. Here, we provide a theoretical solution to this problem by using mathematical analysis and extensive stochastic simulations within the framework of evolutionary rescue theory to determine how best to exploit the vulnerability of small tumours to stochastic extinction. Whereas standard clinical practice is to wait for evidence of relapse, we confirm a recent hypothesis that the optimal time to switch to a second treatment is when the tumour is close to its minimum size before relapse, when it is likely undetectable. This optimum can lie slightly before or slightly after the nadir, depending on tumour parameters. Given that this exact time point may be difficult to determine in practice, we study windows of high extinction probability that lie around the optimal switching point, showing that switching after the relapse has begun is typically better than switching too early. We further reveal how treatment dose and tumour demographic and evolutionary parameters influence the predicted clinical outcome, and we determine how best to schedule drugs of unequal efficacy. Our work establishes a foundation for further experimental and clinical investigation of this evolutionarily-informed "extinction therapy" strategy.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evolutionary rescue model informs strategies for driving cancer cell populations to extinction
Amjad Dabi, Joel S. Brown, … Daniel R. Schrider·PLoS Computational BiologyPeer-reviewed·Sep 18, 2026
- Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies
J. A. Gallaher, P. M. Enriquez-Navas, … A. R. A. Anderson·bioRxiv·Sep 8, 2017
- The logic of containing tumors
Y. Viossat, R. J. Noble·bioRxiv·Jan 22, 2020
- On minimising tumoural growth under treatment resistance
M. M. Fischer, N. Bluethgen·bioRxiv·Jul 4, 2023
- Cancer Evolvability Determines Therapy Outcomes
Ranjini Bhattacharya, Anuraag Bukkuri, … Joel S. Brown·Evolutionary ApplicationsPeer-reviewed·Oct 1, 2026
- Optimal Chemotherapy Scheduling for Non-Genetic Drug Resistance
Sasan Paryad-Zanjani, Michael Saint-Antoine, Abhyudai Singh·bioRxiv·May 11, 2021